A study of LV009 for certain blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer (like non-Hodgkin lymphoma or acute lymphoblastic leukemia) is CD19-positive and has come back or not responded to treatment.
- You are well enough to have a life expectancy of more than 12 weeks and can perform daily activities with some help (ECOG score 0-2).
- Your blood counts, liver, kidney, and heart function are within certain limits.
- You have not had high-dose steroids or strong immune-suppressing drugs within 5 days before the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an investigational cell therapy called LVIVO-TaVec122 for people with certain blood cancers (lymphoma or leukemia) that have come back or not responded to previous treatments. The goal is to see if this new treatment is safe and works for you.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
This study tests a new medicine called LV009 for people with certain blood cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The goal is to see if LV009 is safe and works against these cancers.
This study tests a new cell-based treatment called LV009 in people with certain blood cancers, autoimmune diseases, or antibodies that make transplants difficult. The treatment is meant to fight the disease or reduce harmful antibodies, possibly helping patients who have not responded to other therapies.
This study tests an investigational treatment called B019 for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. It aims to see if this treatment can help when other treatments haven't worked.
Hear when a new Non-Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.